Research programme: rheumatoid arthritis therapies - Cytoguide
Latest Information Update: 09 Oct 2012
At a glance
- Originator Cytoguide
- Class Immunoconjugates
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Oct 2012 No development reported for Rheumatoid arthritis in Denmark (unspecified route)